Outcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use
Top Cited Papers
- 12 November 2009
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 361 (20), 1963-1971
- https://doi.org/10.1056/nejmsa0906126
Abstract
There is good evidence of selective outcome reporting in published reports of randomized trials.Keywords
This publication has 38 references indexed in Scilit:
- Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and PresentationPLoS Medicine, 2008
- Publication of Clinical Trials Supporting Successful New Drug Applications: A Literature AnalysisPLoS Medicine, 2008
- Selective Publication of Antidepressant Trials and Its Influence on Apparent EfficacyThe New England Journal of Medicine, 2008
- When and How Can Endpoints Be Changed after Initiation of a Randomized Clinical TrialPLoS Clinical Trials, 2007
- Empirical Evidence for Selective Reporting of Outcomes in Randomized TrialsJAMA, 2004
- Gabapentin for the treatment of painful diabetic neuropathy: dosing to achieve optimal clinical responseBritish Journal of Diabetes, 2004
- Acknowledgement of Reviewers for 2001European Journal of Neurology, 2002
- Gabapentin vs. Amitriptyline in Painful Diabetic Neuropathy: An Open-Label Pilot StudyJournal of Pain and Symptom Management, 2000
- Glycerol GangliotomyCephalalgia, 1999
- Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boardsJAMA, 1992